Signos Secures $20M to Redefine Weight Loss with AI and Glucose Data

PALO ALTO, CA – May 27, 2026 – Signos, Inc., a health technology company, has secured $20 million in a new funding round to accelerate the adoption of its AI-powered weight management system. The investment, a powerful trifecta of support from tech, medical devices, and insurance, features participation from GV (Google Ventures), CGM giant Dexcom, and Blue Cross Blue Shield of Alabama.

The funding coincides with a strategic partnership that will place the Signos system on Stelo.com, Dexcom’s direct-to-consumer website. This move aims to capitalize on a 10-fold growth surge for Signos over the last six months, fueled by a market increasingly seeking personalized and sustainable health solutions beyond traditional dieting and in the burgeoning era of GLP-1 medications.

At the heart of the company's offering is the first-ever system to receive U.S. Food and Drug Administration (FDA) clearance for an over-the-counter (OTC) continuous glucose monitor (CGM) specifically for weight management purposes, a milestone achieved in March 2025.

The New Frontier of Personalized Health

Signos is pioneering a shift from reactive to proactive health management by giving individuals without diabetes access to real-time metabolic data. The system pairs Dexcom’s Stelo biosensor—a 15-day OTC glucose monitor—with a proprietary mobile application driven by behavioral AI. This combination provides a continuous feedback loop, showing users precisely how their food choices, exercise, sleep, and stress impact their glucose levels.

The FDA clearance (510(k) number K250106) specifically authorizes the system for adults 18 and older not using insulin to help them understand lifestyle impacts on glucose to support healthy weight maintenance. The AI engine analyzes this data, scoring meals and activities to demonstrate how a user’s body is trending toward their goals. It's a departure from one-size-fits-all meal plans, instead fostering what the company calls “metabolic self-knowledge.”

“The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data,” said Sharam Fouladgar-Mercer, CEO and founder of Signos, in a statement. “Signos provides the scoring of every meal with AI, delivering a daily weight loss signal, and giving people the kind of real biological insight that helps users make their results last.”

Strategic Alliances Signal a Market Shift

The composition of the investor group is as significant as the funding itself, signaling broad industry conviction in the future of metabolic health technology. The investment from GV represents a strong vote of confidence from a top-tier venture capital firm known for backing disruptive, technology-first companies.

Dexcom's involvement is multifaceted. As a leading manufacturer of CGMs, its financial investment and partnership underscore a strategic expansion beyond the traditional diabetes market into the broader consumer wellness space. By making Signos available on Stelo.com, Dexcom not only provides a powerful distribution channel but also validates the use of its own hardware for weight management applications.

“Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management,” noted Jon Coleman, Chief Commercial Officer at Dexcom. “Making Signos available on Stelo.com is a natural next step. It makes a powerful, FDA-cleared technology even more accessible for people who are already looking for smarter ways to manage their weight and health.”

Perhaps most tellingly, the participation of Blue Cross Blue Shield of Alabama via its venture arm, 450 Ventures, marks a crucial nod from the payer community. As health insurers grapple with the high costs of obesity-related conditions and expensive GLP-1 medications, they are increasingly looking for cost-effective tools that promote preventative health and sustainable behavioral change. This investment suggests that payers see a tangible value proposition in empowering members with data-driven tools to manage their own metabolic health.

A Data-Driven Companion in the GLP-1 Era

The rapid ascent of GLP-1 medications like Ozempic and Wegovy has transformed the weight loss landscape, but it has also raised questions about long-term sustainability. Many users experience weight regain after discontinuing the drugs. Signos is positioning its platform not as a competitor to these medications, but as a vital companion tool.

While GLP-1s suppress appetite, the Signos system aims to educate users on the underlying metabolic responses that drive weight gain or loss. By learning which foods cause glucose spikes and which combinations promote stability, users can build lasting habits that support weight maintenance, with or without medication. This data-driven foundation provides both users and their doctors a framework for long-term success.

While other companies like Levels Health and NutriSense operate in the same general space of using CGMs for metabolic wellness, Signos’s specific FDA clearance for weight management provides a distinct market advantage and a higher level of regulatory validation. It differentiates the platform from general wellness trackers, positioning it as a dedicated tool for one of the public's most pressing health concerns.

Democratizing Metabolic Monitoring

Ultimately, the convergence of OTC clearance, strategic partnerships, and advanced AI represents a significant step toward democratizing metabolic health. For decades, continuous glucose monitoring was the exclusive domain of diabetes management. Now, this powerful technology is becoming an accessible consumer tool for preventative health.

Research has shown that access to real-time glucose feedback can be a powerful motivator for behavioral change, with studies indicating a high percentage of users alter their food choices and exercise habits based on the data. By translating raw glucose numbers into simple, actionable insights, Signos aims to empower a broader population to move beyond the bathroom scale and engage directly with their own biology.

As tools like the Signos system move from niche biohacking to mainstream wellness, the ability for individuals to proactively manage their metabolic health is becoming a tangible reality, signaling a fundamental change in how we approach long-term well-being.